Drugs IPOs Depend o...
Health Care: Health Services
BG Medicine Inc. (BGMD: NASDAQ)
$1.45 -0.12 | -7.64%
06/18/13 - 04:00 PM ET
Insider Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Net Insider Transaction | 0 | 2.25M | 2.36M | 2.36M | 111,381 | -275,219 | -275,219 |
| Shares Bought | 0 | 2.25M | 2.36M | 2.36M | 111,381 | 23,000 | 23,000 |
| Shares Sold | 0 | 0 | 0 | 0 | 0 | 298,219 | 298,219 |
Institutional Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Total Shares Held | 19.13M | 19.13M | 16.91M | 18.71M | 18.71M | 19.26M | 19.26M |
| Shares Bought | 6.63M | 6.63M | 3.58M | 5.38M | 5.38M | 10.46M | 10.45M |
| Shares Sold | 924,067 | 924,047 | 2.48M | 2.48M | 2.49M | 528,168 | 609,463 |
Portfolios with BGMD
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorUnder-$10 Setting Up To Tra...
- Contributor8 Health Care Stocks With R...
Latest BGMD Headlines from TheStreet
- BG Medicine Welcomes Inclusion Of Galectin-3 As Biomarker Of Myocardial Fibrosis In 2013 ACCF/AHA Guideline For Management Of Heart Failure 06.12.13 | 08:06 am
- BG Medicine Announces Late-Breaker Oral Presentation Of New Data On The BGM Galectin-3(R) Test In Heart Failure 05.28.13 | 08:05 am
- 8 Stocks Under $10 Trending Sharply Higher 05.14.13 | 11:05 pm
- BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 05.10.13 | 05:05 pm
- BG Medicine Appoints Dr. Paul Sohmer As Chief Executive Officer 05.09.13 | 07:05 am
- BG Medicine Reports 2013 First Quarter Financial Results 05.09.13 | 07:05 am
- Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, To Reduce Hospital Readmissions 05.08.13 | 07:05 am
- BG Medicine To Announce First Quarter 2013 Financial Results And Host Conference Call On Thursday, May 9, 2013 05.02.13 | 08:05 am
- BG Medicine Welcomes CE Mark For Galectin-3 Test 04.10.13 | 08:04 am
- BG Medicine Reports Fourth Quarter And Full Year 2012 Financial Results And Provides 2013 Outlook 03.13.13 | 07:03 am
Press Releases for BGMD
- Abbott's Galectin-3 Test Provides Doctors In Europe With New Tool For Assessing The Prognosis Of Chronic Heart Failure Patients - PR Newswire 04.10.13 | 08:04 am
- Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability Of Galectin-3 Testing Service In Partnership With BG Medicine - PR Newswire 03.24.11 | 08:03 am
- BG Medicine Announces Exercise Of Underwriters’ Over-Allotment Option And Closing Of Initial Public Offering - Business Wire 02.09.11 | 04:02 pm
- BG Medicine Announces Pricing Of Initial Public Offering - Business Wire 02.04.11 | 08:02 am
Partner Headlines for BGMD
- Pre-Market Most Active for Dec 12, 2012 : TLAB, QQQ, NRF, STM, BAC, NOK, LLY, AIG, SIRI, BGMD, FB, AAPL - NASDAQ 12.12.12 | 01:12 pm
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- UPDATE: Ladenburg Thalmann Raises PT to $16.50 on BG Medicine - Benzinga 02.14.12 | 01:02 pm
- Market Update - Benzinga 01.09.12 | 09:01 am
